A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

Advances in antiviral therapy have dramatically improved the therapeutic effects on HIV type 1 (HIV-1) infection. However, even with potent combined antiretroviral therapy, HIV-1 latently infected cells cannot be fully eradicated. Latency-reversing agents (LRAs) are considered a potential tool for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Kouki, Kobayakawa, Takuya, Kariya, Ryusho, Tsuchiya, Kiyoto, Ryu, Shoraku, Tsuji, Kohei, Ishii, Takahiro, Gatanaga, Hiroyuki, Yoshimura, Kazuhisa, Okada, Seiji, Hamada, Akinobu, Mitsuya, Hiroaki, Tamamura, Hirokazu, Maeda, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010149/
https://www.ncbi.nlm.nih.gov/pubmed/33815322
http://dx.doi.org/10.3389/fmicb.2021.636276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010149/
https://www.ncbi.nlm.nih.gov/pubmed/33815322
http://dx.doi.org/10.3389/fmicb.2021.636276

Ejemplares similares